Page last updated: 2024-11-05

ticlopidine and Prosthesis Durability

ticlopidine has been researched along with Prosthesis Durability in 35 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."9.15Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."7.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention."7.75Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009)
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models."5.19Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."5.15Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."4.90Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."3.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention."3.75Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."2.79Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
"Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization."2.79Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014)
"Warfarin treatment was an independent predictor of both primary endpoint (OR 1."1.34Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. ( Airaksinen, KE; Airaksinen, TJ; Karjalainen, PP; Niemelä, M; Nyman, K; Porela, P; Vahlberg, T; Vaittinen, MA; Vikman, S; Ylitalo, A, 2007)
"Intimal hyperplasia is one of the main risk factors for the patency of small diameter bypass grafts."1.29[Prevention of vascular intimal hyperplasia in small caliber prostheses. Preliminary results]. ( Baccini, P; Baiardi, A; Cariati, P; Ceppa, P; Civalleri, D; Desalvo, P; Galleano, R; Lenti, E; Simoni, G, 1995)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (5.71)18.2507
2000's15 (42.86)29.6817
2010's18 (51.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almalla, M1
Schröder, J1
Hennings, V1
Marx, N1
Hoffmann, R1
Park, J1
Shin, DH1
Kim, BK1
Her, AY1
Kim, YH2
Choi, HH1
Kim, JS1
Ko, YG1
Choi, D1
Jang, Y1
Hong, MK1
Pergolini, A1
Pino, PG1
Zampi, G1
Polizzi, V1
Musumeci, F1
Silber, S1
Kirtane, AJ1
Belardi, JA1
Liu, M1
Brar, S1
Rothman, M1
Windecker, S2
Camenzind, E1
Boersma, E1
Wijns, W1
Mauri, L1
Rademaker-Havinga, T1
Ordoubadi, FF1
Suttorp, MJ1
Al Kurdi, M1
Steg, PG1
Loh, JP1
Torguson, R1
Pendyala, LK1
Omar, A1
Chen, F1
Satler, LF1
Pichard, AD1
Waksman, R1
Guo, B1
Tan, Q1
Guo, D1
Shi, Z1
Zhang, C1
Guo, W1
Park, SH1
Rha, SW1
Choi, CU1
Kim, EJ1
Oh, DJ1
Cho, YH1
Choi, WG1
Lee, SJ1
Choi, SH1
Kim, WH1
Kim, KC1
Cho, JH1
Kim, JH1
Kim, SM1
Bae, JH1
Bong, JM1
Kang, WY1
Baek, JY1
Seo, JB1
Chung, WY1
Park, MW1
Her, SH1
Suh, J1
Kim, MW1
Kim, YJ1
Choi, HJ1
Soh, JW1
Jeger, RV1
Pfisterer, ME1
Sørensen, R1
von Felten, S1
Alber, H1
Bonetti, PO1
Eberli, F1
Erne, P1
Pedrazzini, G1
Rickli, H1
Galatius, S1
Kaiser, CA1
Schulz-Schüpke, S1
Byrne, RA1
Ten Berg, JM1
Neumann, FJ3
Han, Y1
Adriaenssens, T1
Tölg, R1
Seyfarth, M1
Maeng, M1
Zrenner, B1
Jacobshagen, C1
Mudra, H1
von Hodenberg, E1
Wöhrle, J1
Angiolillo, DJ2
von Merzljak, B1
Rifatov, N1
Kufner, S1
Morath, T1
Feuchtenberger, A1
Ibrahim, T1
Janssen, PW1
Valina, C1
Li, Y1
Desmet, W1
Abdel-Wahab, M1
Tiroch, K1
Hengstenberg, C1
Bernlochner, I1
Fischer, M1
Schunkert, H1
Laugwitz, KL1
Schömig, A2
Mehilli, J1
Kastrati, A2
Schoechlin, S1
Ruile, P1
Pache, G1
Ghodsizad, A1
Badiye, A1
Zeriouh, M1
Pae, W1
Koerner, MM1
Loebe, M1
Barthwal, R1
Herman, BA1
Conroy, MM1
Bolsin, SN1
Pattullo, SJ1
Jayasinghe, R1
Cuisset, T1
Frere, C1
Quilici, J1
Gaborit, B1
Castelli, C1
Poyet, R1
Bali, L1
Morange, PE1
Alessi, MC1
Bonnet, JL1
Giannini, C1
De Carlo, M2
Guarracino, F1
Donne, MG1
Benedetti, G1
Verunelli, F1
Petronio, AS2
Hochholzer, W1
Trenk, D1
Fromm, MF1
Valina, CM1
Stratz, C1
Bestehorn, HP1
Büttner, HJ1
Barison, A1
Bellini, F1
Capozza, PF1
Lunardini, A1
Varenhorst, C1
Koul, S1
Erlinge, D1
Lagerqvist, B1
Siegbahn, A1
Wallentin, L1
James, S1
Linnemann, B1
Thalhammer, A1
Wolf, Z1
Tirneci, V1
Vogl, TJ1
Edelgard Lindhoff-Last, A1
Charlot, M1
Nielsen, LH1
Lindhardsen, J1
Ahlehoff, O1
Olsen, AM1
Hansen, ML1
Hansen, PR1
Madsen, JK1
Køber, L1
Gislason, GH1
Torp-Pedersen, C1
Strecker, EP1
Boos, IB1
Göttmann, D1
Vetter, S1
von Mach, MA1
Eich, A1
Weilemann, LS1
Münzel, T1
Karvouni, E1
Korovesis, S1
Katritsis, DG1
Vats, HS1
Hocking, WG1
Rezkalla, SH1
Gershlick, AH1
Richardson, G1
Wiper, AJ1
Roberts, DH1
Wenaweser, P1
Billinger, M1
Cook, S1
Togni, M1
Meier, B1
Haeberli, A1
Hess, OM1
Karjalainen, PP1
Porela, P1
Ylitalo, A1
Vikman, S1
Nyman, K1
Vaittinen, MA1
Airaksinen, TJ1
Niemelä, M1
Vahlberg, T1
Airaksinen, KE1
Jiménez-Quevedo, P1
Sabaté, M1
Alfonso, F1
Hernández-Antolín, R1
SanMartín, M1
Gómez-Hospital, JA1
Bañuelos, C1
Escaned, J1
Moreno, R1
Fernández, C1
Fernández-Avilés, F1
Macaya, C1
Simoni, G1
Galleano, R1
Ceppa, P1
Desalvo, P1
Cariati, P1
Baccini, P1
Lenti, E1
Baiardi, A1
Civalleri, D1
Oemrawsingh, PV1
Schalij, MJ1
Udayachalerm, W1
van der Wall, EE1
Bruschke, AV1
Shin, EK1
Son, JW1
Sohn, MS1
Jin, DK1
Park, GS1
Koh, KK1
Ahn, TH1
Choi, IS1
Schühlen, H1
Pache, J1
Dirschinger, J1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]2,349 participants (Actual)Observational2008-08-31Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]1,516 participants (Actual)Interventional2008-07-31Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]100 participants (Actual)Interventional2009-03-31Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]Phase 42,292 participants (Actual)Interventional2008-04-30Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]Phase 48,709 participants (Actual)Interventional2007-06-30Completed
Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803]0 participants (Actual)Interventional2013-01-31Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.)
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206]Phase 44,005 participants (Actual)Interventional2008-09-30Active, not recruiting
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement[NCT00457236]800 participants Observational2003-03-31Active, not recruiting
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556]179 participants (Actual)Interventional2003-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Cardiac Death or Target Vessel MI4.2

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)0.9

Death

(NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group1.3

Major Adverse Cardiac Event (MACE)

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group5.5

Stent Thrombosis (ST)

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group0.1

Target Lesion Failure (TLF)

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Primary Enrollment Group4.7

Target Vessel Failure (TVF)

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group6.3

Target Vessel MI

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of eligible participants (Number)
Primary Enrollment Group1.4

In-stent Late Lumen Loss (LLL)

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Interventionmm (Mean)
Zotarolimus Eluting Stent0.13

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

Interventionpercentage of participants with TLF (Number)
Zotarolims Eluting Stent4.0

In-Stent Percent Diameter Stenosis

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

InterventionPercentage diameter stenosis (Mean)
1. Resolute - 12-13 Months21.65
2. XIENCE V - 12-13 Months19.76

Target Lesion Failure

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

Interventionpercentage of participants (Number)
1. Resolute - 12-13 Months8.2
2. XIENCE V - 12-13 Months8.3

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years

Interventionparticipants (Number)
E-ZES61
C-SES75

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

,
Interventionparticipants (Number)
Total death and large non-fatal myocardial infarctTotal death and non-fatal myocardial infarctionsCardiac death and large non-fatal MICardiac death and non-fatal MITarget lesion revascularizationStrokeBleeding events
C-SES25536017428215672184
E-ZES22533115726524977201

Reviews

1 review available for ticlopidine and Prosthesis Durability

ArticleYear
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014

Trials

8 trials available for ticlopidine and Prosthesis Durability

ArticleYear
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin

2014
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
    Trials, 2014, Sep-10, Volume: 15

    Topics: Alloys; Angioplasty, Balloon; Aspirin; Cilostazol; Clinical Protocols; Clopidogrel; Drug Therapy, Co

2014
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El

2014
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
    European heart journal, 2015, May-21, Volume: 36, Issue:20

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-

2015
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Journal of the American College of Cardiology, 2010, Jun-01, Volume: 55, Issue:22

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Confidence

2010
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
    American heart journal, 2011, Volume: 162, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Co

2011
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
    The American journal of cardiology, 2007, Feb-01, Volume: 99, Issue:3

    Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Comb

2007
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    European heart journal, 2007, Volume: 28, Issue:16

    Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death,

2007

Other Studies

26 other studies available for ticlopidine and Prosthesis Durability

ArticleYear
Long-term outcome after angiographically proven coronary stent thrombosis.
    The American journal of cardiology, 2013, May-01, Volume: 111, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-E

2013
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
    European heart journal. Cardiovascular Imaging, 2013, Volume: 14, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co

2013
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
    Journal of cardiac surgery, 2014, Volume: 29, Issue:2

    Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc

2014
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal

2014
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Journal of vascular surgery, 2014, Volume: 60, Issue:4

    Topics: Aged; Alleles; Angiography, Digital Subtraction; Ankle Brachial Index; Arteriosclerosis Obliterans;

2014
Early hypoattenuated leaflet thickening and restricted leaflet motion of a Lotus transcatheter heart valve detected by 4D computed tomography angiography.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, Volume: 11, Issue:5

    Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Clopidogrel; Coronary Angiography; Female;

2015
Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.
    The heart surgery forum, 2016, 12-14, Volume: 19, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Heart Failure; Heart-Assist Devices; Humans; Male; Plat

2016
Very late stent thrombosis after discontinuation of clopidogrel therapy.
    The Medical journal of Australia, 2008, Aug-18, Volume: 189, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studi

2008
Very late stent thrombosis after discontinuation of clopidogrel therapy.
    The Medical journal of Australia, 2009, Feb-02, Volume: 190, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate

2009
Very late stent thrombosis after discontinuation of clopidogrel therapy.
    The Medical journal of Australia, 2009, Feb-02, Volume: 190, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate

2009
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    The American journal of cardiology, 2009, Oct-15, Volume: 104, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins

2009
Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2013, Volume: 14, Issue:7

    Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Clopidogrel; Combined M

2013
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
    Acute cardiac care, 2011, Volume: 13, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug

2011
Late peripheral stent thrombosis due to stent fracture, vigorous exercise and hyporesponsiveness to clopidogrel.
    VASA. Zeitschrift fur Gefasskrankheiten, 2012, Volume: 41, Issue:2

    Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Bicycling; Clopidogrel; Constriction, Pathologic; Dr

2012
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
    European heart journal, 2012, Volume: 33, Issue:20

    Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf

2012
Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results.
    European radiology, 2004, Volume: 14, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Anticoagula

2004
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:2

    Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis

2005
Very late thrombosis after implantation of sirolimus eluting stent.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:6

    Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar

2005
Suspected clopidogrel resistance in a patient with acute stent thrombosis.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary

2006
Drug eluting stents.
    BMJ (Clinical research ed.), 2006, Dec-16, Volume: 333, Issue:7581

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Implants; Humans; Platelet Ag

2006
Stent thrombosis: consider also low response to antiplatelets.
    BMJ (Clinical research ed.), 2007, Jan-13, Volume: 334, Issue:7584

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr

2007
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
    European heart journal, 2007, Volume: 28, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel;

2007
[Prevention of vascular intimal hyperplasia in small caliber prostheses. Preliminary results].
    Minerva cardioangiologica, 1995, Volume: 43, Issue:5

    Topics: Animals; Anticoagulants; Blood Vessel Prosthesis; Disease Models, Animal; Drug Evaluation, Preclinic

1995
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
    Catheterization and cardiovascular diagnosis, 1998, Volume: 44, Issue:2

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp

1998
Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2001, Volume: 52, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor

2001
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
    Journal of the American College of Cardiology, 2001, Jun-15, Volume: 37, Issue:8

    Topics: Aged; Coronary Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregati

2001